2025
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide
Barkmeier A, Deng Y, Swarna K, Herrin J, Polley E, Umpierrez G, Galindo R, Ross J, Mickelson M, McCoy R. Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide. Ophthalmology Retina 2025 PMID: 40774571, DOI: 10.1016/j.oret.2025.07.019.Peer-Reviewed Original ResearchDiabetic macular edemaProliferative diabetic retinopathyComparison of patientsDiabetic retinopathyGLP-1Type 2 diabetesRisk of sight-threatening diabetic retinopathyTreatment of diabetic macular edemaGLP-1 RA treatmentSight-threatening diabetic retinopathyGlucagon-like peptide-1 receptor agonistsScore-weighted Cox proportional hazards modelGLP-1 RA usePeptide-1 receptor agonistsModerate cardiovascular disease riskAdvanced diabetic retinopathyPropensity score-weighted Cox proportional hazards modelsDiabetic retinopathy complicationsEffect of semaglutideGLP-1 RAsRetrospective observational studyCox proportional hazards modelsModerate cardiovascular riskMedicare fee-for-service planRoutine clinical practice
2024
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
Barkmeier A, Herrin J, Swarna K, Deng Y, Polley E, Umpierrez G, Galindo R, Ross J, Mickelson M, McCoy R. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmology Retina 2024, 8: 943-952. PMID: 38735641, PMCID: PMC12233001, DOI: 10.1016/j.oret.2024.05.003.Peer-Reviewed Original ResearchEffects of GLP-1 receptor agonistsSight-threatening diabetic retinopathyGLP-1 receptor agonistsDPP-4 inhibitorsReceptor agonistsDiabetic retinopathySGLT2 inhibitorsDPP-4
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply